Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price ... month, there's been a 1.34% fall in the Zacks Consensus EPS estimate. Eli Lilly ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

I think Eli Lilly and Company's stock correction may be ending ... what the current consensus anticipates (based on historical tendency), the price target for LLY arrives at $945.42.

The firm presently has a “buy” rating on the stock. Citigroup’s target price points ... a PEG ratio of 1.59 and a beta of 0.41. Eli Lilly and Company has a twelve month low of $637.00 ...

Eli Lilly unexpectedly ... with a price/earnings-to-growth ratio (PEG ratio) of 0.3. PEGs below 1 are generally considered undervalued, so on that basis, the stock is very cheap.